The new Merck drug, known as Victrelis, significantly increases the cure rate and shortens treatment for some patients diagnosed with the chronic liver disease. The decision by the U.S. Food and Drug Administration to approve Victrelis was widely expected following a positive recommendation from an outside advisory panel last month.
Merck has not yet disclosed pricing for Victrelis, which is used in combination with long-acting interferon and ribavirin.
>To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: email@example.com